Proteomic analysis of PROSER2 overexpressing cells

ABSTRACT: Pancreatic Ductal Adenocarcinoma (PDAC) is diagnosed at an advanced stage in around 70% of patients and has a dismal 5-year survival rate of less than 11%. This dismal prognosis arises not only due to the absence of diagnostic markers and molecular targets but also due to its aggressive metastatic characteristics. In this research, we took a departure from conventional proteomic studies to identify new molecular targets for pancreatic cancer. We chose uPE1 from an extensive pancreatic cancer proteomic research database and focused our investigation on Proline and Serine Rich 2 (PROSER2), a protein that ranked high in both the cell membrane and cytoplasm. While PROSER2 has been reported to be associated with tumor progression, its exact function remained unclear. In our study using cell lines and patient-derived cells, PROSER2 exhibited a higher expression pattern primarily in cells derived from primary tumors compared to those from metastatic tissues. Overexpression of PROSER2 significantly reduced the metastatic ability of cancer cells, whereas its suppression had the opposite effect. Through proteomic analysis, we discovered that PROSER2 interacts with STK25 and PDCD10, proteins associated with cancer metastatic signaling, and this interaction was confirmed in PROSER2-overexpressing MIAPACA-2 cells. Immunocytochemistry in patient-derived xenograft (PDOX) cells further verified the co-localization of endogenous PROSER2 with STK25 and PDCD10 in the cell membrane and cytoplasm. Taken together, this study is the first to describe the novel role of PROSER2 in antagonizing invasion and proliferation.

INSTRUMENT(S): Orbitrap Fusion Lumos

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: Heeyoun Hwang  

PROVIDER: MSV000092953 | MassIVE |

SECONDARY ACCESSION(S): PXD045646

REPOSITORIES: MassIVE